Almirall
Is an international pharmaceutical company based on innovation and committed to health, headquartered in Barcelona, Spain.
Launch date
Employees
Market cap
AUD3.1b
Enterprise valuation
AUD3.2b (Public information from Sep 2024)
Share price
€8.51 ALM.MC
Barcelona Catalonia (HQ)
Financials
Estimates*
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 1.6b | 827m | 863m | 895m | 975m | 1.1b | 1.2b |
| % growth | 89 % | (49 %) | 4 % | 4 % | 9 % | 11 % | 11 % |
| EBITDA | 226m | 225m | 186m | 167m | 187m | 228m | 271m |
| % EBITDA margin | 14 % | 27 % | 22 % | 19 % | 19 % | 21 % | 23 % |
| Profit | 74.3m | (40.9m) | 4.3m | (38.5m) | 20.5m | 56.2m | 92.9m |
| % profit margin | 5 % | (5 %) | - | (4 %) | 2 % | 5 % | 8 % |
| EV / revenue | 1.4x | 2.7x | 2.0x | 1.9x | 1.9x | 1.6x | 1.4x |
| EV / EBITDA | 10.3x | 9.8x | 9.4x | 10.4x | 10.0x | 7.8x | 6.1x |
| R&D budget | 44.1m | 42.0m | 64.3m | 66.9m | - | - | - |
| R&D % of revenue | 3 % | 5 % | 7 % | 7 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
N/A | Acquisition | ||
* | €200m | Post IPO Equity | |
| Total Funding | - | ||
Recent News about Almirall
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Almirall
Edit
ACQUISITION by Equillium Feb 2022
ACQUISITION by Almirall Dec 2013